On the other hand, a meta-analysis of randomized controlled trials (RCTs) involving type 2 diabetes patients treated with SGLT2 inhibitors found a generally neutral impact on osteomyelitis and PAD, but a link to local ulcers was noted (Nani et al., 2023). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.